Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.

Abstract excerpt

The discovery of the highly prevalent activating JAK (Janus kinase) 2 V617F mutation in myeloproliferative neoplasms, and of other pseudokinase domain-activating mutations in JAK2, JAK1 and JAK3 in blood cancers, prompted great interest in understanding how pseudokinase domains regulate kinase domains in JAKs. Recent functional and mutagenesis studies identified residues required for the V617F mutation to induce...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to JAK1 gene
• Share to JAK3 gene
• Share to TYK2 gene